Sanofi India Limited · NSE:SANOFI
Sanofi India — Q4 2025 Earnings Presentation
15 slides from Sanofi India's earnings presentation, Feb 26, 2026
Slide 1: Exchange filing cover letter for investor call presentation
26th February 2026 The Secretary The Secretary BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor Dalal Street, Mumbai - 400 001 Plot No. C/1, G Block Scrip Code: 500674 Bandra-Kurla Complex, Bandra East Mumbai - 400 050 Symbol: SANOFI Sub: I
Slide 2: Sanofi India Limited Investors call Q4/25
Sanofi India Limited Investors call Q4/25 26 th Fe b ruary 20 26
Slide 3: Disclaimer
Disclaimer This Release / Communication, except for the historical information, may contain statements, including the words or phrases such as expects, anticipates, intends, will, would, undertakes, aims, estimates, contemplates, seeks to, objective, goal, projects, should and similar expressions or
Slide 4: Presenters
Presenters Deepak Arora Rachid Ayari General Manager Pharma India and CFO India and Finance BP Country Lead General Medicines
Slide 5: Sanofi India Limited: 2025 pivotal transformation
Sanofi India Limited 2025 marks a pivotal transformation for Sanofi India Limited. We have fundamentally modernized our business model to position ourselves for sustainable, profitable growth. Business Model Transformation Partnership model Financial Performance Domestic sales Flat for 2025 New orga
Slide 6: Transforming Diabetes Business for Sustainable & Profitable Growth
Transforming Diabetes Business for Sustainable & Profitable Growth 1 2 3 Win with Portfolio Market Expansion Future Ready Go-To- (Basal and Premix) Market Capabilities Market leader: 31% MS Tapping the potential of Customer Centric Volume acceleration:+6% Public Sector Approach Preferred 2 nd gen ba
Slide 7: Diabetes R&D Studies and Pipeline
Diabetes R&D Studies and Pipeline Potential Molecules in LANDMARC RWE Study Soliqua RWE Phase IV study Pipeline Teplizumab CD3 mAb Typ e 1 d iab e t e s, st ag e 3 (US) Scientific evidence dissemination Achieved major milestone of Last Patient and KOL advocacy to address unmet In on 12 December 2025
Slide 8: Total income YTD December/2025 and Q4/2025
₹ in Mio Total income YTD December/2025 Total income Q4/2025 - 9% - 19% 20 .29 7 5.20 8 Sale s 18.726 18 .571 4 .226 (9 2%) 4 .756 Sale s -7% (9 1%) -17% 17.358 (9 3%) 3.9 4 8 (9 3%) -36% Ot he r op 1.4 0 6 1.0 16 -28% Ot he r op inc ome (7%) (5%) inc ome 39 3 250 Ot he r inc ome (8 %) 59 16 5 19 7
Slide 9: Net sales YTD December/2025 and Q4/2025
Net sales YTD December/2025 Net sales Q4/2025 ₹ in Mio Domestic Sales Domestic Sales - 7% +1% 3.76 9 3.4 9 0 15.0 0 0 15.115 1.6 8 0 +11% 6.863 7.29 3 +6% Export Sales 1.8 6 9 Export Sales (4 6 %) (4 8 %) - 40% - 54% 3.725 988 2.24 4 7.515 -2% 1.76 8 -13% 4 58 7.39 0 (50 %) (4 9 %) 1.531 20 24 20 25
Slide 10: Operating expenses 2024-2025
₹ in Mio Operating expenses*| 2024-2025 17% reduction in the quarter & Full year Vs 2024 -17% -17% 5.431 1.468 4.489 1.214 Employees cost 538 Employees cost 2.402 1.853 447 Other OPEX 930 Other OPEX 3.029 767 2.636 FY/24 FY/25 Q4/24 Q4/25 *:Depreciation & finance cost not included as there is no Maj
Slide 11: Profit before tax & exceptional items 2024-2025
Profit before tax & excep items | 2024-2025 ₹ in Mio +1% -27% 1.142 4.691 4.720 830 Profit before tax Profit before tax & exceptional items & exceptional items Q4/24 Q4/25 YTD Dec/24 YTD Dec/25 % Net sales 25% 27% % Ne t sale s 24% 21%
Slide 12: Dividends proposal for the General assembly: +5% Vs 2024
₹ Dividends proposal for the General assembly: +5% Vs 2024 Earning per share 158 142 136 87% 86% 74% Dividend per share 117 117 123 2023 2024 2025
Slide 13: CSR Initiatives – 2025 Update
CSR Initiatives – 2025 Update:Reaching out and building stronger communities Kids & Diabetes in Schools Mobile Medical Units Humanitarian Aid Volunteering Week Education & engagement Health awareness, Non- Timely support to Supporting Health, initiative for diabetes Communicable Diseases families &
Slide 14: Pivotal transformation to position ourselves for sustainable, profitable growth
Sanofi India Limited Pivotal transformation to position ourselves for sustainable, profitable growth Transformed Delivering Positioned Business Model Results Today for Tomorrow Strategic transformation Strong execution driving Future- ready capabilities complete - focus on growth and significant pos
Slide 15: Thank you
Thank you